New Option for Some Patients with Follicular Lymphoma Free

The FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi; Juno Therapeutics) to treat adults with relapsed/refractory follicular lymphoma who have already received at least two other therapies. The decision was based on the results of the phase II TRANSCEND-FL trial, in which patients who had received at least two prior systemic therapies were given a single dose of the CD-19 directed chimeric-antigen receptor therapy. Among 94 evaluable patients, 95.7% responded to the treatment; after a median follow up of 16.8 months, the median duration of response had not been reached.